

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA - Bimekizumab for treating moderate to severe hidradenitis suppurativa

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

It was highlighted that:

- Hidradenitis suppurativa (HS) is more common in women than in men
- People of African-Caribbean family background have a higher incidence than people of European family background

All protected characteristics were considered by committee when making its recommendations. Because its recommendation does not restrict access to treatment for some people over others, this was not considered a potential equality issue.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

A stakeholder also added that HS is more common in women particularly of childbearing age.

Because the committee's recommendation does not restrict access to treatment for some people over others, this was not considered a potential equality issue.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
N/A

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes, in section 3.22

Approved by Associate Director (name):Janet Robertson.....

Date: 26 September 2024